The Pfizer Intelligence Dossier
In boardrooms, around water coolers and behind closed office doors, decision-makers in the pharmaceutical industry are asking questions: What’s happening with Pfizer? What developments have occurred in the last quarter? And how will it affect us?
With Pfizer’s recent US$68 billion acquisition of Wyeth, it’s not surprising. While the multinational giant has refused to seed speculation about potential cuts to its immediate R&D budget, early indications from the combined company suggest it will narrow its focus to cancer, neurological disease, disorders, pain therapy, diabetes, heart and circulatory disease, antibacterial agents and vaccines.
Even more compelling, however, is that the company’s third quarter of 2009 began with news of a 19 per cent drop in second-quarter profit to $2.3 billion, due to a series of missteps and lost patent protections that will inevitably lead to generic brand competition internationally. According to Morgan Stanley investment analysts, "investors have given up on Pfizer's pipeline after a series of failures over the last two years”. Overshadowing that development is major litigation involving Bextra and Neurontin. Yet despite that, the company retains a strong position, with the majority of news reports analyzed as positive.
So what is happening with Pfizer? In a word, plenty. But the real question is: How are you going to keep track of it all?
Key insights on critical industry developments
FirstWord’s new series of Company Intelligence Dossiers provides an overview of Q3 developments in the Pfizer universe, including a detailed snapshot of its position from a financial, corporate, international and R&D point of view. The report analyzes 110 articles published in the media about Pfizer in the third quarter by topic and impact – positive, neutral or negative -- on brand perception as well as what underlies those views, to keep you updated on the company’s strengths and weaknesses.
The report reviews Pfizer’s Q3 progress to establish:
The report
Critical information included in the report
With Pfizer’s recent US$68 billion acquisition of Wyeth, it’s not surprising. While the multinational giant has refused to seed speculation about potential cuts to its immediate R&D budget, early indications from the combined company suggest it will narrow its focus to cancer, neurological disease, disorders, pain therapy, diabetes, heart and circulatory disease, antibacterial agents and vaccines.
Even more compelling, however, is that the company’s third quarter of 2009 began with news of a 19 per cent drop in second-quarter profit to $2.3 billion, due to a series of missteps and lost patent protections that will inevitably lead to generic brand competition internationally. According to Morgan Stanley investment analysts, "investors have given up on Pfizer's pipeline after a series of failures over the last two years”. Overshadowing that development is major litigation involving Bextra and Neurontin. Yet despite that, the company retains a strong position, with the majority of news reports analyzed as positive.
So what is happening with Pfizer? In a word, plenty. But the real question is: How are you going to keep track of it all?
Key insights on critical industry developments
FirstWord’s new series of Company Intelligence Dossiers provides an overview of Q3 developments in the Pfizer universe, including a detailed snapshot of its position from a financial, corporate, international and R&D point of view. The report analyzes 110 articles published in the media about Pfizer in the third quarter by topic and impact – positive, neutral or negative -- on brand perception as well as what underlies those views, to keep you updated on the company’s strengths and weaknesses.
The report reviews Pfizer’s Q3 progress to establish:
- The company’s current financial, corporate and public outlook and position
- An overview of key developments to give competitors critical information
The report
- Offers a concise, visual breakdown of 110 news reports published during the third quarter, analyzed by topic, sentiment and topic addressed
- Outlines key negatives in reporting, such as profit drops, generic brand approvals of Viagra, Cleocin, Lipitor and Ellence, as well as current litigation
- Reviews major global mergers and acquisitions, including the Wyeth takeover, stake holdings in India, initiatives in China and the Nigerian compensation settlements
- Examines R&D as well as marketing news for a wide range of compounds
- Provides substantial financial, product and R&D collaterals to put developments in perspective
Critical information included in the report
- Key patent expiry dates
- Revenue performance by product line
- R&D developments by location, product and disease portfolio
- International news briefs
- Corporate and financial new briefs
PFIZER INC
Recent Financial Results, 2004-2008
NEWS ANALYSIS
NEWS BREAKDOWN
RECENT DEVELOPMENTS
Corporate
Mergers/Acquisitions
Germany
Brazil
Financials
Pfizer
Wyeth
International Developments
Nigeria
India
China
Philippines
South Korea
Venezuela
Slovenia
European Union
Research & Development
Celsentri/Selzentry (maraviroc)
Drug Candidates
Sutent (sunitinib)/Relistor (methylnaltrexone)
PF-02341066
Aromasin (exemestane)
Pain Disorder Compounds
Oncology Portfolio
Karo Bio
Spiriva (tiotropium)
General Pipeline
Torisel (temsirolimus)/Sutent (sunitinib)
PF-03187207
Relistor (methylnaltrexone)
Dimebon (latrepirdine)
PF-04360365/dimebon
Revatio (sildenafil)
Investigational Dermatological Molecules
Marketing & Sales
Caduet Combination Tablets (amlodipine besylate and atorvastatin calcium)
Chantix/Champix (varenicline)
Aricept (donepezil)
Prevenar 13 (Pneumococcal Conjugate Vaccine 13 Valent [Diphtheria CRM197 Protein])
Cleocin (clindamycin)
Diflucan (fluconazole)
PfizerPen G
Idamycin PFS (idarubicin)
Fablyn (lasofoxifene)
rifabutin
Ellence (epirubicin)
Norvasc (amlodipine)
Regulatory Affairs
Health Plan
Wisconsin Fraud Case
Bextra (valdecoxib)
Neurontin (gabapentin)
Lobbying
Reimportation
Co-pay subsidies
Wyeth Acquisition
Strategic Overview
Structure
Operating Structure
Regulatory Progress
Pfizer - Background Information
Key Products
Key Patent Expiry Dates
Revenues Performance – By Product Line
R&D
Groton & New London, Connecticut
Sandwich, United Kingdom
La Jolla, California
St. Louis, Missouri
Rinat, South San Francisco, California
Cambridge, Massachusetts
Ringaskiddy, Cork, Ireland
Mission Bay
Sweden
R&D Portfolio
INDEX
APPENDIX
Recent Financial Results, 2004-2008
NEWS ANALYSIS
NEWS BREAKDOWN
RECENT DEVELOPMENTS
Corporate
Mergers/Acquisitions
Germany
Brazil
Financials
Pfizer
Wyeth
International Developments
Nigeria
India
China
Philippines
South Korea
Venezuela
Slovenia
European Union
Research & Development
Celsentri/Selzentry (maraviroc)
Drug Candidates
Sutent (sunitinib)/Relistor (methylnaltrexone)
PF-02341066
Aromasin (exemestane)
Pain Disorder Compounds
Oncology Portfolio
Karo Bio
Spiriva (tiotropium)
General Pipeline
Torisel (temsirolimus)/Sutent (sunitinib)
PF-03187207
Relistor (methylnaltrexone)
Dimebon (latrepirdine)
PF-04360365/dimebon
Revatio (sildenafil)
Investigational Dermatological Molecules
Marketing & Sales
Caduet Combination Tablets (amlodipine besylate and atorvastatin calcium)
Chantix/Champix (varenicline)
Aricept (donepezil)
Prevenar 13 (Pneumococcal Conjugate Vaccine 13 Valent [Diphtheria CRM197 Protein])
Cleocin (clindamycin)
Diflucan (fluconazole)
PfizerPen G
Idamycin PFS (idarubicin)
Fablyn (lasofoxifene)
rifabutin
Ellence (epirubicin)
Norvasc (amlodipine)
Regulatory Affairs
Health Plan
Wisconsin Fraud Case
Bextra (valdecoxib)
Neurontin (gabapentin)
Lobbying
Reimportation
Co-pay subsidies
Wyeth Acquisition
Strategic Overview
Structure
Operating Structure
Regulatory Progress
Pfizer - Background Information
Key Products
Key Patent Expiry Dates
Revenues Performance – By Product Line
R&D
Groton & New London, Connecticut
Sandwich, United Kingdom
La Jolla, California
St. Louis, Missouri
Rinat, South San Francisco, California
Cambridge, Massachusetts
Ringaskiddy, Cork, Ireland
Mission Bay
Sweden
R&D Portfolio
INDEX
APPENDIX
